Article
The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
The oncologist - 1 Mar 2015
Hasegawa Yoshikazu, Ando Masahiko, Maemondo Makoto, Yamamoto Satomi, Isa Shun-Ichi, Saka Hideo, Kubo Akihito, Kawaguchi Tomoya, Takada Minoru, Rosell Rafael, Kurata Takayasu, Ou Sai-Hong Ignatius
Abstract excerpt
BACKGROUND: Univariate analyses from several randomized phase III trials seemed to suggest ever-smokers with advanced mutated epidermal growth factor receptor (EGFRm) non-small cell lung cancer (NSCLC) did not seem to benefit from EGFR tyrosine kinase inhibitors (TKIs) as first-line treatment when compared with platinum-doublet chemotherapy as measured by progression-free survival (PFS). METHODS: A...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.